Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3231404 | 0.77 | KMT2A (0.49) | KMT2AMEN1GAAHTTSMN1; SMN2 | |
| SCHEMBL5344718 | 0.76 | RAB9A (0.41) | KMT2AMEN1GAASMN1; SMN2L3MBTL1 | |
| SCHEMBL5694237 | 0.72 | EP300 (0.34) | — | |
| SCHEMBL6880479 | 0.69 | KMT2A (0.52) | KMT2AMEN1SMN1; SMN2POLBKDM4E | |
| SCHEMBL5694118 | 0.68 | KMT2A (0.42) | KMT2AMEN1SMN1; SMN2ALOX15KDM4E | |
| SCHEMBL5694209 | 0.68 | GSK3B (0.61) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5694098 | 0.67 | XDH (0.54) | KMT2AMEN1SMN1; SMN2USP2 | |
| SCHEMBL28484041 | 0.66 | MAPK1 (0.54) | KMT2AMEN1GAAHTTSMN1; SMN2 | |
| SCHEMBL1223928 | 0.65 | SMN1; SMN2 (0.39) | GAASMN1; SMN2ALOX15 | |
| SCHEMBL9243904 | 0.64 | ALOX15 (0.95) | KMT2AMEN1SMN1; SMN2POLBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | KMT2A 1088/4885MEN1 467/4885GAA 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.